ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw some unusual options trading on Tuesday. Traders bought 7,765 call options on the company. This represents an increase of approximately 178% compared to the typical volume of 2,789 call options.
ADMA Biologics Stock Performance
Shares of NASDAQ ADMA traded up $0.08 during trading on Friday, hitting $21.31. The company had a trading volume of 2,965,421 shares, compared to its average volume of 3,616,989. ADMA Biologics has a 12 month low of $6.19 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $5.04 billion, a P/E ratio of 76.11 and a beta of 0.53. The stock has a 50 day simple moving average of $18.26 and a 200 day simple moving average of $18.22.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Get Our Latest Stock Report on ADMA
Institutional Investors Weigh In On ADMA Biologics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its stake in shares of ADMA Biologics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company's stock worth $1,408,000 after purchasing an additional 4,865 shares in the last quarter. NorthCrest Asset Manangement LLC purchased a new position in shares of ADMA Biologics in the first quarter valued at about $430,000. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 4,715 shares during the period. Farther Finance Advisors LLC grew its position in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,505 shares in the last quarter. Finally, First Citizens Bank & Trust Co. bought a new stake in ADMA Biologics during the 1st quarter valued at approximately $264,000. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Company Profile
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
